The "Fast Money" traders share their final trades of the day.» Read More
Right now, the hottest part of the market is non-pharma health care because it is immunized from the subprime lending troubles. So each night this week Cramer will highlight one stock from the sector in hopes of finding you the next big thing.
Johnson & Johnson on Monday said it received three subpoenas from U.S. attorneys related to sales and marketing of three of its prescription drugs.
The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.
Boston Scientific and Johnson & Johnson said on Monday that U.S. lawmakers have requested information from the companies on their drug-eluting stents to treat clogged heart arteries.
The news: Concerns that big brokerages such as Lehman Brothers and Goldman Sachs will be left behind as this market recovers? Tim Strazzini said...
Over the last 42 years, he's navigated bull and bear markets, building the best investment track record of all time. And amid this week's market turmoil, the Oracle of Omaha released some words of wisdom. He's buying stocks! Want to know which ones? CNBC's Dylan Ratigan found out where one of the richest men in the world is putting his money.
Searching for nuggets of wisdom from the Oracle of Omaha.
"It's more company-specific news items than anything else," Tony Dwyer, equity market strategist at FTN Midwest Securities, said in an interview with CNBC.com. "You had a very near-term oversold market, you've had a back-and-forth tape over the last few days, so today evens it out."
Johnson & Johnson believes that its non-U.S. subsidiaries made improper payments in connection with the sale of medical devices in two small-market countries, and said its worldwide chairman of medical devices and diagnostics had retired.
Roche reported today that it sold $2.1 billion worth of Tamiflu last year (a 68% increase). Tamiflu is the antiviral that you take shortly after you feel like you've got the flu or as a prophylactic if someone literally close to you has it. But the main driver behind the sales spike last year was government stockpiling of the drug in case of a pandemic.
A not so shameless plug here as we'd like to toot our own horn--as we honor others. Last night, CNBC held it's third annual Executive Leadership Awards dinner--to recognize business leaders who make a difference. The event was at the Pierre Hotel in New York City--and CNBC's Melissa Lee covered it for "Squawk Box."
Stocks in the U.S. are pointing lower this morning. The Fed's statement, important economic data and earnings could all drive the markets today. President Bush speaks on the economy on Wall Street and Treasury Secretary Hank Paulson appears before Senate Banking on the Chinese currency issue.
The findings on Aranesp and colon cancer treatment Vectibix were released late on Thursday, as the world's largest biotechnology company reported a marginal increase in fourth-quarter profit.
As I write this Pfizer shares are down about 2.5% in intra-day trading on top of the 1% loss yesterday. Usually investors cheer when a company announces substantial cost cuts--10,000 jobs, as many as eight facility closures or sales, $1.5 billion-$2 billion in savings by the end of '08. Yesterday you could argue the move was simple selling on the news as the layoffs and cost cuts had been leaked a week ahead of the meeting. But today ...
The diversified health-care company earned $2.17 billion, or 74 cents a share in the fourth quarter, compared with $2.1 billion, or 70 cents, a year earlier.
Stocks in the U.S. for now look headed to open flat to lower-- after yesterday's rocky trading. Europe is moving lower and oil is getting a lift from cold weather. Some big companies will roll out earnings reports today, to a market that has become hypersensitive to corporate earnings growth. Bank America, Johnson & Johnson and DuPont all report today.
The government is considering setting higher standards for birth control drugs used by millions, saying that newer pills appear to be less effective at preventing pregnancy than those approved decades ago.
The drugmaker earned $9.45 billion in the fourth quarter, or $1.32 a share, compared with $2.73 billion, or 37 cents a share, a year earlier.
Wondering how to make big money in drug stocks next year? Two analysts told us their winning prescription for your 2007 portfolio on today’s “Morning Call.” Their advice: Look for (positive) newsmakers and buy into generics.
After the market close yesterday Pfizer, in an SEC filing, revealed that ousted Chairman and CEO Hank McKinnell will walk away with nearly $200 million in pension benefits, deferred compensation and other cash and stock including more than $300,000 in unused vacation time. This is well above the pension benefits that had been reported earlier this year and includes money that had not previously been disclosed. A Pfizer spokesman says the company is honoring its legal obligation to meet the terms of McKinnell's employment contract which was signed in 2001--"a different time in the company's history," he said.